Dextran
( DrugBank: Dextran / KEGG DRUG: Dextran 1, Dextran sulfate sodium, Dextran 40, Dextran 70, Dextran 75 )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 2 |
| 62 | Paroxysmal nocturnal hemoglobinuria | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 96 | Crohn disease | 1 |
| 97 | Ulcerative colitis | 8 |
2. Amyotrophic lateral sclerosis
Clinical trials : 786 / Drugs : 550 - (DrugBank : 182) / Drug target genes : 170 - Drug target pathways : 232
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
62. Paroxysmal nocturnal hemoglobinuria
Clinical trials : 358 / Drugs : 160 - (DrugBank : 35) / Drug target genes : 33 - Drug target pathways : 116
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
96. Crohn disease
Clinical trials : 2,737 / Drugs : 1,197 - (DrugBank : 240) / Drug target genes : 182 - Drug target pathways : 221
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
97. Ulcerative colitis
Clinical trials : 3,305 / Drugs : 1,646 - (DrugBank : 318) / Drug target genes : 165 - Drug target pathways : 220
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|